Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924270 | 0.85 | ALDH1A1 (0.37) | ALDH1A1GAAALOX12HTTHIF1A | |
| SCHEMBL6751624 | 0.82 | LMNA (0.31) | ALDH1A1GAAALOX12HTTHIF1A | |
| SCHEMBL6357268 | 0.82 | POLB (0.41) | CD44ALDH1A1GAATP53CYP3A4 | |
| SCHEMBL29671489 | 0.82 | LMNA (0.31) | CD44ALDH1A1GAAALOX12HTT | |
| SCHEMBL5573258 | 0.82 | LMNA (0.31) | CD44ALDH1A1GAAALOX12HTT | |
| SCHEMBL3295814 | 0.82 | CD44 (0.41) | CD44ALDH1A1GAAALOX12HTT | |
| SCHEMBL841515 | 0.74 | CYP3A4 (0.48) | CD44ALDH1A1GAAALOX12HTT | |
| SCHEMBL2922690 | 0.74 | KDM4E (0.42) | ALDH1A1GAACYP3A4THRBALOX15 | |
| SCHEMBL11220054 | 0.74 | ALDH1A1 (0.43) | ALDH1A1HIF1AMAOAMAOB | |
| SCHEMBL2928246 | 0.74 | KDM4E (0.42) | ALDH1A1GAACYP3A4THRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | CD44 4444/4885ALDH1A1 3546/4885GAA 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.